TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6781659
Drug: No regular
Normalized name: Aveeno Regular Bath
Approvals — FDA: no, EMA: no, PMDA: no
Description: No regular maintenance treatment
Study: 27940571
Drug: Assertive Community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive Community Treatment (ACT) plus Treatment as Usual (TAU)
Study: 15170977
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IFL and bevacizumab
Study: 12752559
Drug: Non-hypotensive haemorrhage
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-hypotensive haemorrhage (5.6 +/- 1.2 ml kg-1 body weight)
Study: 30044438
Drug: Almond snack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almond snack (56.7 g/day; 364 kcal; n = 38)
Study: 30044438
Drug: Graham cracker
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graham cracker control (77.5 g/day; 338 kcal/d; n = 35)
Study: 19889469
Drug: Intensive multifactorial
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive multifactorial treatment (stepwise implementation of behavior modification, pharmacological therapy targeting hyperglycaemia, hypertension, dyslipidaemia, and proteinuria)
Study: 16268465
Drug: CVL type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVL type (peripherally inserted central catheters, untunneled CVL, tunneled exteriorized CVL, subcutaneous ports)
Study: 12297918
Drug: Intravenous prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prostaglandin E1 (PGE1), n = 18
Study: 12297918
Drug: No PGE1
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No PGE1 treatment (PGE1(-) group), n = 26
Study: 11074998
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy alone (active control)
Study: 8777102
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (240 kJ h‐1, infused over 1‐2 h before anaesthesia)
Study: 2000818
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg beta-carotene/d orally
Study: 6653137
Drug: Actifed Compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actifed Compound
Study: 29142294
Drug: GnRH 10
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH 10 μg
Study: 29142294
Drug: GnRH 50
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH 50 μg
Study: 29142294
Drug: GnRH 100
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH 100 μg
Study: 29142294
Drug: GnRH (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH (all doses)
Study: 27084861
Drug: Coconut oil
Normalized name: Coconut Oil
DrugBank: Coconut oil (DB14322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut oil pulling (10 ml for 10 minutes)
Study: 27084861
Drug: Chlorhexidine mouthwash
Normalized name: chlorhexidine Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine mouthwash (5 ml for 1 minute)
Study: 27084861
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water (5 ml for 1 minute)
Study: 23006479
Drug: High-dose ascorbic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ascorbic acid intravenously before exercise
Study: 20339913
Drug: Capecitabine 1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine 1,250 mg/m2 (1,000 mg/m2 in patients >65 years) BID on days 1-14 q3w
Study: 15907777
Drug: Active dose
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active dose of alcohol (0.65 g/kg)
Study: 11821453
Drug: Trastuzumab 4
Normalized name: TRASTUZUMAB 440MG/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab 4 mg/kg loading dose, followed by 2 mg/kg weekly
Study: 11821453
Drug: Trastuzumab 8
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab 8 mg/kg loading dose, followed by 4 mg/kg weekly
Study: 7717559
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg bolus plus infusion of 150 micrograms.kg‐1.min‐1)
Study: 8455371
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody against human C5a
Study: 26506890
Drug: Personalized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized treatment strategy based on patient information
Study: 25676405
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia only in group G
Study: 25676405
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (GP and G)
Study: 20731585
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream applied during scaling
Study: 20731585
Drug: No EMLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No EMLA cream applied during scaling
Study: 19902797
Drug: Combined supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined supplement of 40 mg of zinc as zinc gluconate and 40 mg of iron as ferrous sulphate
Study: 19902797
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of elemental iron as ferrous sulphate
Study: 10664922
Drug: Duloxetine 20
Normalized name: duloxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 20 mg bid, escalated to 30 mg bid, then to 40 mg bid
Study: 7817443
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (short-term intensive weekly instillation)
Study: 7817443
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of short-term and 3-year protocols
Study: 3041327
Drug: Morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (10 mg i.m.)
Study: 30364350
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment (n = 7)
Study: 21081801
Drug: L-tryptophan 500
Normalized name: L-TRYPTOPHAN 500MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan 500 mg twice daily and Essentiale forte 3 times a day for 4 weeks
Study: 21081801
Drug: Melatonin 5
Normalized name: melatonin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5 mg twice a day and Essentiale forte 3 times a day for 4 weeks
Study: 16198932
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.8 g/kg/day)
Study: 12456423
Drug: Nalbuphine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 4 mg (Group N)
Study: 12456423
Drug: Droperidol 0.625
Normalized name: droPERidol 0.625 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.625 mg plus nalbuphine 4 mg (Group ND)
Study: 2569323
Drug: Prescription Information
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription Information Leaflets (PILs) distributed by pharmacists or general practitioners
Study: 2569323
Drug: No Prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Prescription Information Leaflets (Control)
Study: 25803783
Drug: BCAA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA and arginine supplementation (0.17 g/kg BCAA and 0.04 g/kg arginine)
Study: 21327794
Drug: L +
Normalized name: Citracal + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: L + A (leg exercises before elbow flexor training)
Study: 19739491
Drug: Enriched formula
Normalized name: STRESS FORMULA 500,BIOTIN ENRICHED TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched formula (Kcal: 75/100 ml, proteins: 2 g/100 ml)
Study: 19739491
Drug: Standard formula
Normalized name: Standard formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formula (Kcal: 67/100 ml, proteins: 1.4 g/100 ml)
Study: 15037328
Drug: Gatifloxacin 400
Normalized name: gatifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 400 mg once daily
Study: 15037328
Drug: Gatifloxacin 200
Normalized name: gatifloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 200 mg once daily
Study: 11319653
Drug: Sibutramine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (10 mg/day) with a low-fat low-energy individualized diet (600 kcal/day deficit)
Study: 9874862
Drug: Sufentanil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (10 micrograms) added to 12.5 mg of 0.5% bupivacaine
Study: 7857761
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitors (enalapril, captopril)
Study: 348532
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 600 mg
Study: 31668721
Drug: 1.5 L
Normalized name: NUTREN 1.5 LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 L of Sterofundin ISO (Reference arm A)
Study: 31668721
Drug: 0.5 L
Normalized name: AIR 20.5 L in 100 L RESPIRATORY (INHALATION) GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 L of 4% Gelaspan® (Isoeffective arm B)
Study: 31668721
Drug: 0.5 L
Normalized name: AIR 20.5 L in 100 L RESPIRATORY (INHALATION) GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 L of 4% Gelaspan® and 1 L of Sterofundin ISO (Isovolumetric arm C)
Study: 31163434
Drug: Uric acid
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uric acid 1,000 mg
Study: 25845864
Drug: delafloxacin 300
Normalized name: delafloxacin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: delafloxacin 300 mg i.v. (therapeutic)
Study: 25845864
Drug: delafloxacin 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: delafloxacin 900 mg i.v. (supratherapeutic)
Study: 25845864
Drug: moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: moxifloxacin 400 mg orally (positive control)
Study: 24158584
Drug: Monitored group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitored group (no further treatment)
Study: 22264450
Drug: glucose syrup/sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: glucose syrup/sucrose (glc/suc)
Study: 16305977
Drug: benazepril 20
Normalized name: benazepril 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril 20 mg/day
Study: 16305977
Drug: benazepril 10
Normalized name: benazepril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril 10 mg/day plus valsartan 80 mg/day
Study: 2496173
Drug: Zidovudine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (250 mg every 4 hours)
Study: 2496173
Drug: Ribavirin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (800 mg or 600 mg daily)
Study: 710312
Drug: Combined low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined low-dose heparin and acetylsalicyl-lysine (given intravenously)
Study: 710312
Drug: Increased heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased heparin dosage (3 X 7500 IU/24 h)
Study: 710312
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not receiving any heparin)
Study: 31414266
Drug: Parent-based weight-loss
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-based weight-loss treatment for children with ASD (PBT-ASD)
Study: 25730000
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (kidney-reinforcing and blood-activating), N = 35
Study: 23618450
Drug: 1 session
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 session daily (OD)
Study: 23618450
Drug: 1 session
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 session weekly with optional deliberate practice (WD)
Study: 23618450
Drug: 1 session
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 session weekly (C)
Study: 23618450
Drug: 3 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 sessions daily (TD)
Study: 21067912
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and magnesium infusions (Ca/Mg(+))
Study: 21067912
Drug: No calcium
Normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No calcium and magnesium infusions (Ca/Mg(-))
Study: 15001406
Drug: Mean time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean time to analgesic administration
Study: 11315920
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus medroxy progesterone acetate (hormone therapy)
Study: 9278766
Drug: Cumulative minimum
Normalized name: sipuleucel-T
DrugBank: Sipuleucel-T (DB06688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative minimum thermal isoeffect dose (equivalent minutes at 43 degrees C)
Study: 9278766
Drug: MINTIME >
Approvals — FDA: no, EMA: no, PMDA: no
Description: MINTIME > 42 degrees C (first treatment session)
Study: 9278766
Drug: %sensors >
Approvals — FDA: no, EMA: no, PMDA: no
Description: %sensors > 43 degrees C (peak, second treatment session)
Study: 8315435
Drug: Interferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2a (gradually escalating doses from 3 to 36 x 10(6) U subcutaneously administered daily)
Study: 8315435
Drug: Interferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2a (daily)
Study: 8315435
Drug: Interferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2a (daily) + vinblastine (0.15 mg/kg every 3 weeks)
Study: 3099564
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg BID
Study: 3099564
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg HS
Study: 3099564
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg HS
Study: 3099564
Drug: Cimetidine 1200
Normalized name: cimetidine 1200 mg-0.9%/500 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1200 mg HS (nonrandomized)
Study: 27646578
Drug: Fish Oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish Oil (FO) alone (1.9 g DHA + EPA/day)
Study: 27646578
Drug: EGCG alone
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG alone (600 mg/day)
Study: 27646578
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FO and EGCG
Study: 22952184
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (100 μg Se as l-selenomethionine)
Study: 20724342
Drug: High-dose telmisartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose telmisartan (2 mg/kg/d)
Study: 20724342
Drug: Low-dose telmisartan
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose telmisartan (1 mg/kg/d)
Study: 11872029
Drug: Digital rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rectal examination (DRE) and transrectal ultrasonography (TRUS) as initial screening tests
Study: 10091520
Drug: Nifedipine-GITS (NIF,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine-GITS (NIF, 30 mg/d)
Study: 10091520
Drug: Hydrochlorothiazide (HCTZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ, 25 mg/d)
Study: 10091520
Drug: Nifedipine-GITS (NIF,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine-GITS (NIF, 30 mg/d) + Hydrochlorothiazide (HCTZ, 25 mg/d)
Study: 7751519
Drug: Cetirizine dihydrochloride
Normalized name: Cetirizine dihydrochloride
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetirizine dihydrochloride 0.25 microgram/ml
Study: 7751519
Drug: Cetirizine dihydrochloride
Normalized name: Cetirizine dihydrochloride
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetirizine dihydrochloride 1.0 and 2.5 micrograms/ml
Study: 7751519
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 and 20 mg/day
Study: 1979241
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cetirizine b.i.d.
Study: 1979241
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg terfenadine b.i.d. (Control)
Study: 23695900
Drug: Phonomotor treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonomotor treatment (60 hours over 6 weeks)
Study: 15678052
Drug: Antiarrhythmic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic therapy for 1 week (group A)
Study: 15678052
Drug: Antiarrhythmic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic therapy for 3 weeks (group B)
Study: 15678052
Drug: Antiarrhythmic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic therapy for 6 weeks (group C)
Study: 12707430
Drug: Venlafaxine 225
Normalized name: venlafaxine 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 225 mg
Study: 8916821
Drug: High-dose tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tranexamic acid (maximum of 20 g)
Study: 1670840
Drug: calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcipotriol ointment 50 micrograms/g
Study: 1670840
Drug: betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: betamethasone valerate ointment 0.1%
Study: 30924154
Drug: DSP-0565 administered
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DSP-0565 administered orally to rats and dogs
Study: 29916979
Drug: Deliberate practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deliberate practice combined with speech therapy based on the Whole Language Model
Study: 29916979
Drug: Speech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech therapy based on the Whole Language Model (Control)
Study: 26663215
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy using methyl aminolaevulinate (MAL, 80 mg g(-1))
Study: 22320349
Drug: Exenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10 µg subcutaneous injection)
Study: 17414741
Drug: Milnacipran 25
Normalized name: milnacipran 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran 25 mg twice daily, then 50 mg twice daily until the 10th week
Study: 16263999
Drug: Heliox (70%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heliox (70% helium, 30% oxygen) driven nebulized albuterol (15 mg/hour)
Study: 16263999
Drug: Oxygen (100%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen (100% oxygen) driven nebulized albuterol (15 mg/hour)
Study: 12537614
Drug: Voice therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice therapy intervention
Study: 9699783
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (early use)
Study: 9699783
Drug: Different drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different drugs or different doses of drug
Study: 8729740
Drug: Glycerin (GL)
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerin (GL) placebo patches
Study: 2172349
Drug: Nedocromil sodium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedocromil sodium, 1% nasal solution, one spray per nostril, four times daily for 8 weeks
Study: 2172349
Drug: Cromolyn sodium,
Normalized name: Cromolyn Sodium, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn sodium, 4% nasal solution, one spray per nostril, four times daily for 8 weeks
Study: 2172349
Drug: Placebo, one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, one spray per nostril, four times daily for 8 weeks
Study: 21639923
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (specific formula not detailed)
Study: 8844923
Drug: Maternal behavioral
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal behavioral and psychosocial factors (e.g., smoking, low weight for height, negative mood, rejection of pregnancy)
Study: 1727997
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Curosurf (200 mg/kg)
Study: 1727997
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of Curosurf (200 mg/kg initial dose + 2 additional doses of 100 mg/kg each)